title: Enhanced expression of Fas Ligand (FasL) in the lower airways of patients with fibrotic interstitial lung diseases (ILDs).
abstract: The exact role of FasL, and particularly its soluble and membrane-bound forms, in the development of chronic ILDs and lung fibrosis has not been extensively explored. We aimed at analyzing membrane-bound FasL expression on alveolar macrophages (AM) and lymphocytes (AL) as well as soluble FasL (sFasL) levels in bronchoalveolar lavage (BAL) from ILDs patients, incl. pulmonary sarcoidosis (PS), hypersensitivity pneumonitis (HP), silicosis, asbestosis, idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), and healthy subjects (n = 89, 12, 7, 8, 23, 6, 17, respectively). In IPF, significantly increased percentage of AM FasL(+) and CD8(+)FasL(+) cells as well as sFasL levels in BAL were found. Increased sFasL levels were also observed in HP. NSIP and asbestosis were characterized by higher AM FasL(+) relative number; CD8(+)FasL(+) population was expanded in asbestosis only. There was a significant decline in AL FasL(+) percentage in PS and HP. Vital capacity was negatively correlated with sFasL levels, AM FasL(+) and CD8(+)FasL(+) cell relative count. CD4(+)FasL(+) and CD8(+)FasL(+) percentage strongly correlated with BAL neutrophilia, an unfavorable prognostic factor in lung fibrosis. The concurrent comparative BAL analysis of FasL expression indicates that FasL(+) AM and AL (mainly Tc cells) comprise an important element of the fibrotic process, mostly in IPF. FasL might play a crucial role in other fibrosis-complicated ILDs, like NSIP and asbestosis.
authors.affiliation: Department of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. mpkopins@hotmail.com
authors.forename: Piotr
authors.initials: P
authors.lastname: Kopiński
authors.forename: Barbara
authors.initials: B
authors.lastname: Balicka-Ślusarczyk
authors.forename: Andrzej
authors.initials: A
authors.lastname: Dyczek
authors.forename: Adam
authors.initials: A
authors.lastname: Szpechciński
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Przybylski
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Jarzemska
authors.forename: Tomasz
authors.initials: T
authors.lastname: Wandtke
authors.forename: Marek
authors.initials: M
authors.lastname: Jankowski
authors.forename: Teresa
authors.initials: T
authors.lastname: Iwaniec
authors.forename: Joanna
authors.initials: J
authors.lastname: Chorostowska-Wynimko
mesh_terms: D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry*; D053222:Fas Ligand Protein / Q000378:metabolism*; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000276:immunology / Q000378:metabolism*; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism; D016676:Macrophages, Alveolar / Q000276:immunology / Q000378:metabolism; D011658:Pulmonary Fibrosis / Q000276:immunology / Q000378:metabolism; D017565:Sarcoidosis, Pulmonary / Q000276:immunology
chemical_list: D053222:Fas Ligand Protein